



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

Artificial Intelligence in Pharmacovigilance: Current Applications and Future Perspectives

Hiten Thakkar, Mansi Vasava, Vankar Padamdas, Pathak Shailly, Dr. Ria Memoria*

Neotech Institute of Pharmacy, Vadodara, Gujarat, India.

ARTICLE INFO

Published: 12 Oct 2026

Keywords:

Artificial Intelligence, Pharmacovigilance, Adverse Drug Reactions, Machine Learning, Natural Language Processing, Signal Detection, Drug Safety.

DOI:

10.5281/zenodo.23320478

ABSTRACT

Pharmacovigilance (PV) is the science and practice of detecting, assessing, understanding, and preventing adverse drug reactions (ADRs) and other medication-related problems. The increasing volume of healthcare data generated through electronic health records, spontaneous reporting systems, biomedical literature, social media platforms, and realworld evidence databases has created significant challenges for traditional pharmacovigilance methods. Artificial Intelligence (AI), including machine learning (ML), deep learning (DL), natural language processing (NLP), and large language models (LLMs), has emerged as a transformative technology capable of improving drug safety surveillance. AI-based approaches facilitate automated signal detection, adverse event identification, duplicate report detection, causality assessment, and pharmacovigilance workflow optimization. Recent studies demonstrate that machine-learning models often outperform conventional statistical methods in identifying safety signals while reducing manual workload. Despite these advances, challenges related to data quality, algorithmic bias, interpretability, regulatory acceptance, and ethical concerns remain barriers to widespread implementation. This review discusses the current applications of AI in pharmacovigilance, evaluates existing evidence, highlights limitations, and explores future perspectives for integrating AI into routine drug safety monitoring.

INTRODUCTION

Pharmacovigilance is a fundamental component of modern healthcare that ensures the continuous monitoring of the safety, efficacy, and quality of pharmaceutical products throughout their

lifecycle. According to the World Health Organization (WHO), pharmacovigilance encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary objective of

***Corresponding Author:** Dr. Ria Memoria

Address: Neotech Institute of Pharmacy, Vadodara, Gujarat, India.

Email ✉: riamemoria2711@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



pharmacovigilance is to protect public health by identifying adverse drug reactions (ADRs) at the earliest possible stage, thereby enabling regulatory authorities, healthcare professionals, and pharmaceutical companies to implement appropriate risk management strategies and improve patient safety.

Conventional pharmacovigilance systems rely predominantly on spontaneous adverse event reporting databases such as the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), the European Medicines Agency's EudraVigilance, and the World Health Organization's global database, VigiBase. These databases collect millions of individual case safety reports (ICSRs) submitted by healthcare professionals, patients, and pharmaceutical manufacturers. Over the past several decades, these systems have played a crucial role in identifying previously unknown adverse drug reactions, issuing safety warnings, updating product labeling, and, when necessary, withdrawing unsafe medicines from the market.

Despite their significant contributions, traditional pharmacovigilance systems face several well-recognized challenges. These include underreporting of adverse drug reactions, delayed reporting, incomplete or inconsistent clinical information, duplicate case reports, reporting bias, and the increasing complexity associated with managing massive volumes of heterogeneous safety data. Furthermore, the continuous growth of electronic health records, scientific publications, clinical trial databases, patient registries, wearable devices, and social media platforms has generated an unprecedented amount of structured and unstructured data that exceeds the processing capacity of conventional manual pharmacovigilance methods. Consequently, there is a growing need for advanced computational

technologies capable of rapidly analyzing these large datasets while maintaining high levels of accuracy and reliability.

Recent advances in Artificial Intelligence (AI) have created new opportunities to overcome many of these limitations. AI refers to computer systems that can perform tasks requiring human intelligence, including learning, reasoning, pattern recognition, natural language understanding, and decision-making. In pharmacovigilance, AI technologies—including machine learning (ML), deep learning (DL), natural language processing (NLP), and large language models (LLMs)—enable automated processing of vast quantities of safety information from diverse sources. These techniques improve the efficiency of adverse event identification, literature screening, case processing, duplicate detection, signal detection, and risk assessment while significantly reducing manual workload and processing time.

The application of AI in pharmacovigilance has evolved considerably over the past decade. Early pharmacovigilance systems were primarily based on rule-based algorithms and statistical disproportionality methods for identifying potential safety signals. However, modern AI-driven approaches utilize sophisticated machine learning models capable of recognizing complex patterns within multidimensional datasets, identifying previously unrecognized adverse drug reactions, predicting drug safety risks, and supporting evidencebased regulatory decision-making. These intelligent systems continuously improve their performance by learning from new safety data, thereby enhancing the sensitivity and specificity of signal detection.

Recent scientific reviews have highlighted the growing integration of AI into nearly every stage of the pharmacovigilance workflow, including signal detection, validation, prioritization,



causality assessment, literature surveillance, case triage, regulatory reporting, and post-marketing safety monitoring. Several studies have demonstrated that AI-based approaches outperform conventional frequentist statistical methods in specific pharmacovigilance applications by detecting emerging safety signals earlier, reducing falsepositive results, and improving overall operational efficiency. As pharmaceutical data continue to expand in both volume and complexity, AI is expected to become an indispensable component of next-generation pharmacovigilance systems, supporting faster, more accurate, and proactive drug safety monitoring while ultimately improving patient outcomes and public health.

OVERVIEW OF ARTIFICIAL INTELLIGENCE IN PHARMACOVIGILLIGENCE

Artificial Intelligence (AI) is a branch of computer science that enables machines to perform tasks that typically require human intelligence, including learning, reasoning, decision making, pattern recognition, and language understanding. In pharmacovigilance, AI has emerged as a transformative technology capable of improving the efficiency, accuracy, and speed of drug safety monitoring. The increasing volume of data generated from spontaneous reporting systems, electronic health records, clinical trials, biomedical literature, patient registries, wearable devices, and social media platforms has created significant challenges for traditional pharmacovigilance systems. AI provides advanced computational methods to process these heterogeneous datasets, identify hidden safety signals, predict adverse drug reactions (ADRs), and support evidence-based regulatory decision-making.

Unlike conventional pharmacovigilance approaches that rely heavily on manual review and statistical disproportionality analyses, AI-based systems can continuously learn from new data and improve their predictive performance over time. Modern AI technologies—including Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and Large Language Models (LLMs)—are increasingly being integrated into pharmacovigilance workflows to automate case processing, literature surveillance, signal detection, duplicate identification, causality assessment, and risk prediction. These technologies enhance operational efficiency, reduce manual workload, minimize human error, and facilitate earlier identification of emerging drug safety concerns. Consequently, AI is becoming an essential component of next-generation pharmacovigilance systems aimed at improving patient safety and public health.

1. Machine Learning

Machine Learning (ML) is a subset of artificial intelligence that enables computer systems to learn patterns from historical data and make predictions or decisions without being explicitly programmed. In pharmacovigilance, ML algorithms analyze large volumes of structured and unstructured safety data to identify associations between drugs and adverse events. Unlike traditional statistical approaches, machine learning models continuously improve their performance as more data become available, making them particularly valuable for postmarketing drug safety surveillance.

Machine learning has numerous applications in pharmacovigilance, including signal detection, prediction of adverse drug reactions, duplicate case identification, risk stratification, causality assessment, case prioritization, and automated quality control. Supervised learning algorithms



such as Random Forests, Support Vector Machines (SVM), Gradient Boosting Machines (GBM), Logistic Regression, and Artificial Neural Networks have demonstrated excellent performance in identifying potential drug safety signals.

Unsupervised learning techniques, including clustering algorithms, are useful for discovering hidden relationships and identifying previously unrecognized adverse drug reactions. Several studies have reported that machine learning models outperform conventional disproportionality methods by improving sensitivity, specificity, and overall signal detection performance while reducing false-positive findings. Furthermore, ML algorithms facilitate real-time pharmacovigilance surveillance by continuously analyzing incoming safety reports and identifying emerging risks more rapidly than traditional approaches. [1]

2. Deep Learning

Deep Learning (DL) is an advanced branch of machine learning that utilizes multilayer artificial neural networks capable of learning highly complex and nonlinear relationships from large datasets. Unlike conventional machine learning algorithms that require manual feature engineering, deep learning models automatically extract meaningful features directly from raw data, making them highly effective for analyzing large-scale biomedical information.

In pharmacovigilance, deep learning has become increasingly important for processing unstructured data sources such as clinical narratives, scientific publications, electronic health records, and social media posts. Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Long Short-Term Memory (LSTM) networks, and Transformer-based architectures have been

successfully applied for adverse event classification, biomedical text mining, literature screening, signal detection, and social media monitoring. Deep learning models can recognize subtle patterns within multidimensional datasets that are often difficult to identify using traditional statistical methods. These capabilities enable earlier identification of potential safety signals, improved extraction of adverse event information, and enhanced predictive modeling of drug-related risks. Although the adoption of deep learning in pharmacovigilance has grown considerably during the past decade, its implementation remains relatively limited compared with other healthcare domains due to challenges related to data quality, computational requirements, interpretability, and regulatory validation. Nevertheless, ongoing advances in computational power and explainable AI are expected to accelerate its integration into routine pharmacovigilance practice. [2]

3. Natural Language Processing

Natural Language Processing (NLP) is a specialized area of artificial intelligence that enables computers to understand, interpret, analyze, and generate human language. Since a substantial proportion of pharmacovigilance data exists in unstructured textual formats, NLP has become one of the most valuable AI technologies for drug safety surveillance. Safety-related information is frequently found in clinical notes, discharge summaries, scientific literature, electronic medical records, patient forums, spontaneous adverse event reports, product labels, and social media platforms.

NLP techniques automatically extract relevant clinical entities such as drug names, adverse drug reactions, indications, dosages, patient demographics, and temporal relationships from free-text documents. These extracted data are subsequently converted into structured datasets



suitable for statistical analysis and signal detection. Modern NLP approaches employ transformer-based language models, including Bidirectional Encoder Representations from Transformers (BERT) and other large language models, which significantly improve information extraction accuracy compared with traditional rule-based systems. NLP also supports automated literature screening, case narrative summarization, duplicate detection, MedDRA coding, literature surveillance, multilingual safety monitoring, and regulatory reporting. By reducing the need for manual review of extensive textual data, NLP enhances the speed, consistency, and accuracy of pharmacovigilance operations while enabling more efficient detection of emerging drug safety concerns. [5]

CURRENT APPLICATIONS OF AI IN PHARMACOVIGILANCE

1. Automated Adverse Event Detection

Artificial intelligence enables the automatic detection of adverse drug reactions (ADRs) by analyzing large volumes of reports from spontaneous reporting systems. Machine learning algorithms identify unusual reporting patterns that may indicate new safety concerns more quickly and accurately than conventional statistical methods, improving early signal detection.

2. Signal Detection and Signal Management

AI plays a key role in all stages of signal management, including signal detection, validation, prioritization, and evaluation. Advanced machine learning models can process large pharmacovigilance databases efficiently and have shown improved performance in identifying both known and previously unrecognized drug safety signals.

3. Literature Screening and Case Processing

AI-powered natural language processing (NLP) systems automate the screening of scientific literature by identifying publications containing adverse event information. These systems extract relevant safety data and prioritize important reports for expert review, reducing manual workload and accelerating case processing.

4. Social Media Pharmacovigilance

Patients often share their medication experiences on social media platforms and online health forums. AI and NLP technologies analyze these unstructured data sources to detect potential adverse drug reactions and emerging safety issues, providing valuable supplementary information for pharmacovigilance activities.

5. Real-World Evidence Analysis

Artificial intelligence analyzes real-world data from electronic health records, insurance claims, and patient registries to identify associations between medicines and adverse events. These insights support regulatory decision-making, post-marketing surveillance, and the evaluation of long-term drug safety.

6. Causality Assessment

AI-based machine learning models assist in determining whether a drug is responsible for an adverse event by integrating patient characteristics, drug exposure history, clinical outcomes, and other relevant factors. Although human expertise remains essential, AI improves the consistency and efficiency of causality assessment.

LARGE LANGUAGE MODELS AND GENERATIVE AI



The emergence of large language models (LLMs) such as ChatGPT has introduced new possibilities for pharmacovigilance.

Potential applications include:

- Safety narrative generation
- Case summarization
- Literature review support
- Medical information retrieval
- Regulatory document preparation

However, LLMs remain susceptible to hallucinations, factual inaccuracies, and inconsistent outputs. Consequently, human oversight remains essential for all safety-critical applications.

Large Language Models (LLMs), such as ChatGPT, have introduced new opportunities to improve pharmacovigilance by automating language-based tasks and supporting safety professionals. These models can generate safety narratives, summarize adverse event cases, assist in literature reviews, retrieve medical information, and support the preparation of regulatory documents. By reducing manual workload, LLMs improve efficiency and accelerate pharmacovigilance activities. However, they may produce inaccurate or fabricated information (hallucinations) and inconsistent responses. Therefore, all AI-generated outputs must be carefully reviewed and validated by qualified pharmacovigilance experts before use in regulatory or clinical decision-making.

BENEFITS OF ARTIFICIAL INTELLIGENCE (AI) IN PHARMACOVIGILANCE

Artificial Intelligence (AI) provides numerous advantages in pharmacovigilance by improving

the speed, accuracy, and efficiency of drug safety monitoring. The major benefits include:

1. Early Detection of Safety Signals

- AI can analyze large volumes of adverse event reports and identify potential safety signals much earlier than traditional methods, enabling timely regulatory action.

2. Automation of Case Processing

- AI automates repetitive tasks such as adverse event intake, duplicate detection, coding of medical terms, and case triage, reducing manual workload.

3. Improved Accuracy

- Machine learning and natural language processing (NLP) reduce human errors in data extraction, classification, and adverse event identification.

4. Faster Data Analysis

- AI processes millions of reports from multiple sources within minutes, significantly reducing the time required for signal detection and safety assessments.

5. Efficient Literature Monitoring

- NLP-based systems automatically screen scientific literature, medical journals, and online databases to identify relevant adverse drug reaction (ADR) reports.

6. Enhanced Signal Detection

- AI algorithms detect complex patterns and hidden associations between drugs and adverse events that may not be recognized through conventional statistical methods.



7. Cost and Time Savings

- Automation reduces operational costs, minimizes manual effort, and increases overall productivity in pharmacovigilance operations.

8. Real-Time Monitoring

- AI enables continuous surveillance of safety data from spontaneous reporting systems, electronic health records, social media, and medical databases.

9. Better Decision Support

- AI assists pharmacovigilance professionals by providing data-driven insights for causality assessment, risk evaluation, and regulatory decision-making.

10. Improved Regulatory Compliance

- AI helps maintain consistency in documentation, supports timely reporting, and facilitates preparation of regulatory safety documents such as Periodic Safety Update Reports (PSURs).

11. Integration of Multiple Data Sources

- AI combines information from electronic health records, clinical trials, insurance claims, wearable devices, and social media to provide a comprehensive view of drug safety.

12. Support for Personalized Medicine

- AI identifies patient-specific risk factors and predicts adverse drug reactions based on demographic, genetic, and clinical information, contributing to safer and more personalized treatment.

AI is transforming pharmacovigilance by enabling faster, more accurate, and more efficient monitoring of drug safety throughout a medicine's lifecycle. While AI significantly enhances signal detection, case processing, and decision support, human expertise remains essential to validate findings, interpret results, and ensure regulatory compliance in safety-critical activities.

CHALLENGES AND LIMITATIONS

Although Artificial Intelligence (AI) has transformed pharmacovigilance by improving the speed and efficiency of safety monitoring, several challenges and limitations continue to hinder its widespread adoption. Addressing these issues is essential to ensure reliable, ethical, and regulatory-compliant use of AI in drug safety.

1. Data Quality and Availability

AI systems rely heavily on high-quality, standardized, and complete datasets. However, pharmacovigilance data often contain missing information, duplicate reports, inconsistent terminology, and reporting bias. Poor-quality data can reduce the accuracy and reliability of AI models, leading to incorrect predictions or missed safety signals.

2. Lack of Explainability (Black-Box Models)

Many advanced AI models, particularly deep learning algorithms, function as "black boxes," making it difficult to understand how they arrive at specific decisions. This lack of transparency limits trust among healthcare professionals and regulatory authorities, especially for safety-critical decisions.

3. Regulatory and Compliance Challenges

Current pharmacovigilance regulations require transparent, validated, and auditable processes. AI



systems must comply with Good Pharmacovigilance Practices (GVP), Good Machine Learning Practice (GMLP), and data privacy regulations. However, regulatory frameworks for AI in pharmacovigilance are still evolving.

4. Bias and Generalizability

AI algorithms may inherit biases present in training datasets, resulting in unequal performance across different populations, ethnic groups, or geographic regions. Models trained on limited datasets may fail to generalize to diverse real-world clinical settings.

5. Data Privacy and Security

Pharmacovigilance databases contain sensitive patient information. The use of AI requires strict adherence to data protection laws and secure handling of patient records to prevent unauthorized access and maintain confidentiality.

6. High Implementation Costs

Developing, validating, and maintaining AI-based pharmacovigilance systems requires significant investment in infrastructure, software, computational resources, and skilled personnel. These costs may limit adoption, particularly in low- and middle-income countries.

7. Integration with Existing Systems

Many pharmaceutical companies continue to use legacy pharmacovigilance databases and workflows. Integrating AI technologies into existing systems can be technically complex and may require substantial changes to established processes.

8. Need for Human Oversight

AI should support rather than replace pharmacovigilance professionals. Expert review remains essential for case assessment, causality evaluation, signal validation, and regulatory decision-making. Human oversight is particularly important because AI models can generate false-positive or false-negative results.

9. Limited Availability of Annotated Data

Supervised machine learning requires large volumes of accurately labelled training data. Creating high-quality annotated pharmacovigilance datasets is labor-intensive, time consuming, and requires domain expertise.

10. Ethical Considerations

The use of AI raises ethical concerns regarding algorithmic fairness, accountability, transparency, and responsibility for AI-generated decisions. Clear governance frameworks are needed to ensure ethical deployment in pharmacovigilance.

11. Hallucinations in Large Language Models (LLMs)

Generative AI models such as ChatGPT can occasionally produce inaccurate or fabricated information ("hallucinations"). Therefore, outputs generated by LLMs should always be verified by qualified pharmacovigilance professionals before being used in regulatory documents or clinical decision-making.

Despite these challenges, AI remains a highly promising technology for modern pharmacovigilance. Improvements in data quality, model transparency, regulatory guidance, validation methods, and human-AI collaboration will be essential to maximize its benefits while ensuring patient safety. AI is expected to augment, rather than replace, pharmacovigilance



professionals by enabling faster, more accurate, and more efficient drug safety monitoring.

FUTURE PERSPECTIVES

Artificial intelligence is expected to play an increasingly important role in the future of pharmacovigilance by improving the speed, accuracy, and efficiency of drug safety monitoring. Several emerging technologies and regulatory developments are likely to transform pharmacovigilance practices in the coming years.

1. Real-Time Safety Monitoring

AI-powered systems will enable continuous analysis of electronic health records, spontaneous reporting systems, wearable devices, and social media data, allowing earlier detection of adverse drug reactions (ADRs) and faster regulatory action.

2. Advanced Predictive Analytics

Machine learning and deep learning models will increasingly predict potential safety risks before they become widespread, enabling proactive risk management and personalized patient safety strategies.

3. Integration of Large Language Models (LLMs)

Large language models such as ChatGPT and other generative AI tools are expected to assist in:

- Automated case narrative generation
- Case summarization
- Medical literature review
- Signal assessment support
- Preparation of regulatory documents

- Medical information retrieval

However, human expert review will remain essential to ensure accuracy and regulatory compliance.

4. Personalized Pharmacovigilance

Future AI systems will combine genetic information, patient demographics, lifestyle factors, and medical history to predict individual susceptibility to adverse drug reactions, supporting precision medicine.

5. Improved Global Data Integration

Cloud computing and interoperable databases will facilitate secure sharing of pharmacovigilance data among pharmaceutical companies, healthcare providers, and regulatory agencies, improving worldwide signal detection.

6. Automation of Routine Pharmacovigilance Activities

Robotic Process Automation (RPA) combined with AI will automate repetitive tasks such as:

- Case intake
- Duplicate detection
- Data entry
- Coding using MedDRA
- Quality checks
- Report generation

This will allow pharmacovigilance professionals to focus on complex medical assessments.

7. Enhanced Regulatory Decision-Making



Regulatory authorities are expected to increasingly adopt AI-assisted tools for benefit-risk assessment, signal prioritization, and post-marketing surveillance while developing standardized guidelines for AI validation and governance.

8. Explainable and Ethical AI

Future AI systems will emphasize transparency, interpretability, fairness, and accountability. Explainable AI (XAI) will help regulators and healthcare professionals understand how AI reaches safety-related decisions, thereby increasing trust and acceptance.

9. Digital Health and Wearable Integration

Data from wearable devices, mobile health applications, and remote patient monitoring systems will provide continuous real-world safety information, enabling earlier identification of drug-related adverse events.

10. Human–AI Collaboration

Rather than replacing pharmacovigilance professionals, AI will function as a decision-support tool. Human expertise will remain indispensable for clinical judgment, causality assessment, signal validation, and regulatory decision-making.

The future of pharmacovigilance will be driven by intelligent, data-driven technologies that enable earlier detection of safety signals, improved operational efficiency, and more personalized patient care. Despite these advances, successful implementation will depend on high-quality data, robust regulatory frameworks, ethical AI practices, and continued human oversight to ensure patient safety and public trust.

CONCLUSION

Artificial intelligence has emerged as a transformative technology in pharmacovigilance, significantly improving the efficiency, accuracy, and speed of drug safety monitoring. AI-powered tools, including machine learning, natural language processing, deep learning, and large language models, have enhanced adverse event detection, signal management, literature surveillance, case processing, and real-world evidence analysis. These advancements enable the rapid analysis of large and complex datasets, supporting earlier identification of potential safety risks and more informed regulatory decision-making.

Despite these benefits, the widespread adoption of AI in pharmacovigilance is accompanied by important challenges, including data quality issues, algorithmic bias, lack of transparency, ethical concerns, regulatory uncertainty, and the need for robust validation. Therefore, AI should be regarded as a decision-support tool rather than a replacement for human expertise. Continuous human oversight, standardized validation frameworks, and compliance with evolving regulatory guidelines are essential to ensure the safe and responsible implementation of AI technologies.

In the future, collaborative human–AI systems are expected to become the cornerstone of pharmacovigilance, combining computational efficiency with clinical and regulatory expertise. As AI technologies continue to evolve, their integration into pharmacovigilance workflows has the potential to strengthen global drug safety systems, improve patient outcomes, optimize resource utilization, and support proactive, data-driven pharmacovigilance practices. Ultimately, responsible adoption of AI will play a pivotal role in advancing the quality, reliability, and



effectiveness of drug safety monitoring worldwide.

REFERENCES

1. Warner J, Jardim AP, Albera C. Artificial Intelligence: Applications in
2. Pharmacovigilance Signal Management. *Pharm Med.* 2025;39:183–198.
3. Nagar A, Gobburu J, Chakravarty A. Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration. *Ther Adv Drug Saf.* 2025.
4. Roche V, Robert JP, Salam H. AI-based Approach for Safety Signals Detection from Social Networks. 2022.
5. Zhao Y, Yu Y, Wang H, et al. Machine Learning in Causal Inference: Application in Pharmacovigilance. *Drug Saf.* 2022;45:459–476.
6. Senthil Kumar RK, Velusamy S. Harnessing Artificial Intelligence for Enhanced Pharmacovigilance: A Comprehensive Review. *Indian J Pharm Pract.* 2025;18(2):171–179.
7. Karthikeyan J, Osoro I, Rajanandh MG. Integrating AI in Pharmacovigilance: A New Era of Drug Safety and Risk Management. *J Chem Health Risks.* 2026.
8. Koletsas P, Gavazova E, Staynova R, et al. Application of Artificial Intelligence in Pharmacovigilance: A Systematic Review. 2025.
9. Beam AL, Kompa B, Hakim JB, et al. Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review. *Drug Saf.* 2022;45:477–49
10. Applications of artificial intelligence in current pharmacy practice: A scoping review
11. Role of artificial intelligence in pharmacy practice: a narrative review
12. Artificial intelligence in clinical pharmacy—A systematic review of current scenario and future perspectives
13. Artificial intelligence in the field of pharmacy practice: A literature review
14. Applications of AI in pharmacy practice: a look at hospital and community settings
15. Assessing the accuracy and consistency of ChatGPT in clinical pharmacy management: a preliminary analysis with clinical pharmacy experts worldwide
16. Using artificial intelligence in health-system pharmacy practice: finding new patterns that matter
17. Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies
18. Artificial intelligence in pharmaceutical technology and drug delivery design
19. Molecular representations in AI-driven drug discovery: a review and practical guide
20. Concepts of artificial intelligence for computer-assisted drug discovery
21. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0)
22. Reducing inappropriate polypharmacy: the process of deprescribing
23. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review
24. Artificial intelligence in drug discovery: recent advances and future perspectives
25. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting
26. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review

HOW TO CITE: Hiten Thakkar, Mansi Vasava, Vankar Padamdass, Pathak Shailly, Dr. Ria Memoria, Artificial Intelligence in Pharmacovigilance: Current Applications and Future Perspectives, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 10, 1540-1550. <https://doi.org/10.5281/zenodo.23320478>

